Want to join the conversation?
$GILD said that non-GAAP product GM was 87.2% for 1Q16 vs. 90.9% in 1Q15. The dip in GM reflects a $200MM charge or $0.12 EPS related to the jury verdict in the Merck trial in March. The company posted non-GAAP R&D expenses of $769MM, a rise of 18% vs. 1Q15 due to the continued progression of clinical studies.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?